Bionano Projects 56% Revenue Growth in FY27, EBITDA Break-Even by Q4 FY27
BNGO sits 24% above its 52-week low of $1.
Summary
Bionano's investor presentation sets FY27 revenue guidance of $50-54M (56% growth) and projects adjusted EBITDA break-even by Q4 FY27, while highlighting a Medicare coverage determination for OGM published for public comment.
Key Events · Earnings and Guidance · BNGO
-
FY27 Revenue Guidance of $50-54M
Management projects 56% year-over-year revenue growth to $50-54M in FY27, up from $31-33M guided for FY26.
-
Adjusted EBITDA Break-Even by Q4 FY27
The company expects adjusted EBITDA to reach approximately $0 exit rate in Q4 FY27, with full-year FY27 adjusted EBITDA of ($8.5M) improving to $2.1M in FY28 and $17.3M in FY29.
-
Medicare Coverage Determination Published
MolDX published a local coverage determination (LCD) for OGM in hematologic malignancies for public comment on August 27, 2026. Billing is expected to become active after the comment period and technical assessment.
-
New York State Approval Unlocks MSKCC
New York State approval of the laboratory heme workflow enables Memorial Sloan Kettering Cancer Center to offer OGM testing.
Analysis · BNGO · Industrial Applications And Services
Bionano's investor presentation at the H.C. Wainwright conference introduces FY27 revenue guidance of $50-54M — a 56% year-over-year jump — and projects adjusted EBITDA break-even by Q4 FY27. That is a meaningful step toward profitability for a company that reiterated a going-concern warning just last month with only $3.7M in cash. The presentation also highlights a Medicare coverage determination (MolDX LCD) published for public comment on August 27, 2026, which could unlock reimbursement for OGM testing in hematologic malignancies. Against the backdrop of urgent capital needs, this forward guidance and reimbursement progress give investors a concrete path to sustainability.
How filings like this one have moved
In the 30 days to Oct 2, 2026, 29.5% of the 1629 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.59%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, BNGO was trading at $1.24 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $14.4M. The 52-week trading range was $1.00 to $5.50. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.